Overview

• Biopharmaceutical company's Q4 revenue rose significantly, driven by Attruby product sales

• Company reported positive Phase 3 trial results for multiple drugs

• Company issued $632.5 mln convertible notes to fund operations

Outlook

• BridgeBio plans NDA submission for BBP-418 in 1H 2026, U.S. launch late 2026/early 2027

• Company expects NDA submission for encaleret in 1H 2026, U.S. launch late 2026/early 2027

• BridgeBio anticipates NDA submission for infigratinib in 2H 2026, launch early to mid 2027

Result Drivers

• ATTRUBY SALES - Attruby net product revenue increased by 35% quarter-over-quarter, driven by its differentiated profile and continued prescribing growth

• FINANCIAL POSITION - Issuance of $632.5 mln convertible notes in January 2026 to fund planned commercial and pipeline operations

Company press release: ID:nGNX8qbj9j

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 22 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for BridgeBio Pharma Inc is $96.00, about 41.4% above its February 23 closing price of $67.91

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)